A Randomized, Open-label, Single Dose, Three-period, Six-sequences, Crossover Study of High-fat and Low-fat Meal Effect on the Pharmacokinetics of Apatinib Mesylate in Chinese Healthy Adult Subjects
Latest Information Update: 25 Oct 2021
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 19 Oct 2021 Status changed from not yet recruiting to completed.
- 13 Apr 2020 New trial record